Woloszczuk W - Search Results

1

Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum.

Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W. Hawa G, et al. Among authors: woloszczuk w. Clin Lab. 2003;49(9-10):461-3. Clin Lab. 2003. PMID: 14572201

2

Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis.

Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A. Skoumal M, et al. Among authors: woloszczuk w. Ann Rheum Dis. 2004 Feb;63(2):216-7. doi: 10.1136/ard.2002.004507. Ann Rheum Dis. 2004. PMID: 14722219 Free PMC article. No abstract available.

3

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.

Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A. Skoumal M, et al. Among authors: woloszczuk w. Rheumatol Int. 2005 Nov;26(1):63-9. doi: 10.1007/s00296-004-0579-1. Epub 2005 May 12. Rheumatol Int. 2005. PMID: 15889303

4

Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.

Ziegler S, Niessner A, Richter B, Wirth S, Billensteiner E, Woloszczuk W, Slany J, Geyer G. Ziegler S, et al. Among authors: woloszczuk w. Metabolism. 2005 Jul;54(7):935-8. doi: 10.1016/j.metabol.2005.02.009. Metabolism. 2005. PMID: 15988704

5

Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.

Zojer N, Brenner K, Beke D, Kudlacek S, Hawa G, Woloszczuk W, Hofbauer LC, Pecherstorfer M. Zojer N, et al. Among authors: woloszczuk w. Anticancer Res. 2005 Sep-Oct;25(5):3607-12. Anticancer Res. 2005. PMID: 16101188 Clinical Trial.

6

Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men.

Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P. Kerschan-Schindl K, et al. Among authors: woloszczuk w. Exp Clin Endocrinol Diabetes. 2008 Aug;116(8):491-5. doi: 10.1055/s-2007-993142. Epub 2007 Dec 10. Exp Clin Endocrinol Diabetes. 2008. PMID: 18072013

7

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.

Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P. Mikosch P, et al. Among authors: woloszczuk w. Eur J Clin Invest. 2006 Aug;36(8):566-73. doi: 10.1111/j.1365-2362.2006.01678.x. Eur J Clin Invest. 2006. PMID: 16893379

8

IFCC committee on markers for bone turnover and bone disease--project presentation.

Woloszczuk W. Woloszczuk W. Scand J Clin Lab Invest Suppl. 1997;227:95-9. Scand J Clin Lab Invest Suppl. 1997. PMID: 9127474 Review.

9

Big-endothelin release in baboon bacteremia is partially TNF dependent.

Redl H, Schlag G, Bahrami S, Kargl R, Hartter W, Woloszczuk W, Davies J. Redl H, et al. Among authors: woloszczuk w. J Lab Clin Med. 1994 Dec;124(6):796-801. J Lab Clin Med. 1994. PMID: 7798792

10

Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.

Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, Stanek B. Koller-Strametz J, et al. Among authors: woloszczuk w. J Heart Lung Transplant. 1998 Apr;17(4):356-62. J Heart Lung Transplant. 1998. PMID: 9588580

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results